Table 3.

Comparison of baseline and overall survival for all subjects, those age 18-70 only, in RT+TMZ+EMD to EORTC phase III cohort

Trial	RT+TMZ+EMD	EORTC Phase III
	Age 18-70 (n=101)	Age 18-70 (n=287)
	No. of patients (%)	No. of patients (%)
Baseline:
Age Median (range), yr	55 (23-70)	56 (19-70)
KPS, 90-100	72 (71)	249 (86)
Surgery, Debulking	77 (76)	239 (83)
Corticosteroids, yes	75 (76)	193 (67)
Histology, GBM	101 (100)	221 (92)
Outcome:
Median overall survival (95% CI)	20.7 (17-24)	14.6 (13-17)
% overall survival at 24 months (95% CI)*	41 (31 -51)	27 (21-32)

^*p< 0.05